Cognitive impairment in chronic obstructive pulmonary disease

Citation for published version (APA):

van Beers, M., Janssen, D. J. A., Gosker, H. R., & Schols, A. M. W. J. (2018). Cognitive impairment in chronic obstructive pulmonary disease: disease burden, determinants and possible future interventions. *Expert Review of Respiratory Medicine*, 12(12), 1061-1074. <https://doi.org/10.1080/17476348.2018.1533405>

Document status and date:

Published: 02/12/2018

DOI:

[10.1080/17476348.2018.1533405](https://doi.org/10.1080/17476348.2018.1533405)

Document Version:

Publisher's PDF, also known as Version of record

Document license:

Taverne

Please check the document version of this publication:

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

[Link to publication](#)

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

www.umlib.nl/taverne-license

Take down policy

If you believe that this document breaches copyright please contact us at:

repository@maastrichtuniversity.nl

providing details and we will investigate your claim.

Cognitive impairment in chronic obstructive pulmonary disease: disease burden, determinants and possible future interventions

Martijn van Beers, Daisy J. A. Janssen, Harry R. Gosker & Annemie M. W. J. Schols

To cite this article: Martijn van Beers, Daisy J. A. Janssen, Harry R. Gosker & Annemie M. W. J. Schols (2018) Cognitive impairment in chronic obstructive pulmonary disease: disease burden, determinants and possible future interventions, Expert Review of Respiratory Medicine, 12:12, 1061-1074, DOI: [10.1080/17476348.2018.1533405](https://doi.org/10.1080/17476348.2018.1533405)

To link to this article: <https://doi.org/10.1080/17476348.2018.1533405>

Accepted author version posted online: 08 Oct 2018.
Published online: 14 Oct 2018.

Submit your article to this journal [↗](#)

Article views: 217

View Crossmark data [↗](#)

REVIEW

Cognitive impairment in chronic obstructive pulmonary disease: disease burden, determinants and possible future interventions

Martijn van Beers ^a, Daisy J. A. Janssen^{b,c}, Harry R. Gosker^a and Annemie M. W. J. Schols^a

^aDepartment of Respiratory Medicine, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Centre+, Maastricht, The Netherlands; ^bDepartment of Research & Education, CIRO, Centre of Expertise for Chronic Organ Failure, Horn, The Netherlands; ^cCentre of Expertise for Palliative Care, Maastricht University Medical Centre+, Maastricht, The Netherlands

ABSTRACT

Introduction: Cognitive impairment (CI) is an important but an under-recognized extra-pulmonary feature of chronic obstructive pulmonary disease (COPD). It is related to the burden of disability, worse health outcomes, and impaired self-management.

Areas covered: CI includes deterioration of a wide range of cognitive functions, such as memory and various executive functions. Risk of hospitalization might be higher in patients with COPD compared to those without, with CI negatively impacting the wellbeing of patients with COPD. Disease-specific factors such as hypoxemia and inflammation, lifestyle factors such as dietary insufficiencies and lack of physical activity, and comorbidities such as obstructive sleep apnea and depression are likely to synergistically contribute to the development of CI in COPD. Tailored interventions can possibly improve CI in COPD, but this needs further investigation.

Expert commentary: Further research is warranted involving the optimization of neuropsychological testing for screening and outcome assessment, longitudinal studies to investigate the development of CI in COPD over time, and randomized clinical trials to test the feasibility and efficacy of promising interventions.

ARTICLE HISTORY

Received 30 May 2018

Accepted 4 October 2018

KEYWORDS

COPD; cognitive impairment; pathology

1. Introduction

Chronic obstructive pulmonary disease (COPD) is a chronic lung disease characterized by persistent respiratory symptoms and airflow limitation due to airway and/or alveolar abnormalities [1]. It is well established that common extra-pulmonary comorbidities such as heart failure, osteoporosis, and muscle wasting contribute significantly to the disease burden [2]. Moreover, recent research shows that cognitive impairment (CI) is also a common and important, yet under-investigated comorbidity [3]. This review will discuss various aspects related to CI in COPD: its prevalence and characteristics, related health outcomes, determinants, and possible interventions to maintain or improve cognitive functioning in patients with COPD.

2. Cognitive functioning

Cognition can be defined as any brain function that enables an individual to perceive, register, store, retrieve, and use information in order to adapt behavior to new situations and function in our environment [4]. Cognition consists of many separate domains, including memory, working memory, and attention [5].

Cognition is organized hierarchically and different cognitive functions can be classified as 'lower' or 'higher' [6] (see Figure 1). The lower functions form the basis for the higher functions, including the executive functions such as inhibition (choosing an option that is more rewarding in the longer term

instead of the more immediately satisfying option when presented with a choice, for example, refusing the attempt to smoke a cigarette) and cognitive flexibility (being able to swiftly shift mental resources, for example, changing the type of physical activity undertaken in case of weather changes) [7]. Executive functioning in turn underlies even more complex processes such as problem-solving and decision-making, for example, when and how to undertake action in case of increased symptom severity (e.g., disease exacerbation or unintended weight loss).

Specific brain areas do not exclusively perform a single task, but many brain areas are specialized for certain types of tasks (see Figure 2). The language and memory systems are largely located in the temporal lobe, whereas the higher-order functions such as inhibition, cognitive flexibility, reasoning, and decision-making are processed in the frontal lobe. Subcortical structures are located within the brain, including the hippocampus, which plays a central role in memory encoding; the limbic system, including the amygdala and cingulate cortex, which are involved in fear and pain processing; and the basal ganglia, including the caudate nucleus, which is involved in movement but also in learning and remembering [8].

Brain damage, for instance, caused by brain atrophy or degeneration, can contribute to the development of CI. This is an inevitable part of aging, but acute and chronic disease can accelerate it. In the initial stages of CI development,

Figure 1. A hierarchical view of cognitive processes. Adapted from Cleutjens et al. [4].

Figure 2. (a) View of the left hemisphere, indicating the areas mentioned in the text. (b) Sagittal view of the brain, indicating the areas mentioned in the text. Adapted from Patrick J. Lynch, medical illustrator, and C. Carl Jaffe, MD, cardiologist.

impairments are noticeable, but not severe enough to impair activities of daily living; a stage called mild cognitive impairment (MCI) [5]. MCI often, but not always, involves impairments in memory rather than in other domains [9], and it may progress into Alzheimer's disease [9] or remain stable [10].

3. Cognitive impairment in COPD

Patients with COPD display impairment in cognitive domains as diverse as attention, executive functioning [3,11–13], (visual) memory and reproduction [14,15], problem-solving, concentration, logical and abstract reasoning, planning, coordination, and organization [3]. Thus, the pattern of impairments is diffuse, and not every patient is affected or suffers from CI to the same degree in different cognitive domains [16]. This diffuse pattern resembles aging-related cognitive deterioration and is consistent with the view of CI in COPD as a manifestation of accelerated aging [3]. On the other hand, patients with Alzheimer's

disease or other dementias show a much more specific pattern of CI.

3.1. Prevalence

3.1.1. Cross-sectional studies

A recent meta-analysis pooled 14 studies investigating the prevalence of CI in COPD patients [17]. The average prevalence of any CI (5 studies, $N = 2,995$) was 32%. MCI was present in 25% of patients (11 studies, $N = 4,663$). Higher prevalence of CI was associated with respiratory disease severity, dependence in activities of daily living and poor quality of life [17].

Studies published after this meta-analysis (25 February 2016) show an even higher prevalence of CI (see Tables 1, 2). Two studies by Cleutjens *et al.* reported CI, determined by extensive neuropsychological assessment, in 56.7% and 41.5% of patients with COPD referred for pulmonary rehabilitation (PR) [18,19]. In the former study, only 13.3% of non-COPD age-matched controls suffered from CI. Pierobon *et al.* showed that the Montreal Cognitive Assessment (MoCA) score of 9.5% of patients admitted

Table 1. Overview of studies investigating the prevalence of CI in COPD.

Study (First author, year)	Country	Design	Setting	Population	Sample size	Gender (% male)	Mean age (SD)
Cleutjens, 2017a [18]	Netherlands	cross-sectional	PR	Clinically stable COPD admitted to PR	90	54.4	63.7 ± 8.8
Cleutjens, 2017b [19]	Netherlands	cross-sectional	PR	Clinically stable COPD admitted to PR	76	60.5	62.7 ± 8.7
Cleutjens, 2017c [61]	Netherlands	cross-sectional	PR	non-CI controls with COPD Clinically stable COPD admitted to PR	107 157	47.7 50.3	63.7 ± 9.9 62.9 ± 9.4
Lopez-Torres, 2016 [25]	Spain	longitudinal	hospital	Patients hospitalized with and recovering from acute COPD exacerbation	62	75.8	68.32 ± 7.43
Pierobon, 2017 [20]	Italy	observational, cross-sectional	PR	Stable (no exacerbations for the last 3 months) COPD patients with GOLD stage II-IV, group C-D	84	75.0	70.2 ± 7.0
Park, 2018 [27]	USA	observational, longitudinal	NETT	Participants with radiological evidence of bilateral emphysema, severe airflow obstruction and hyperinflation, and the ability to complete PR	307	59.6	66.2 ± 5.7
Roncero, 2016 [21]	Spain	cross-sectional	respiratory medicine department	Ambulatory patients > 40 years with stable COPD	940	81.6	67.6 ± 10.0
Samareh Fekri, 2017 [23]	Iran	cross-sectional	medical university	Patients with a history and symptoms of COPD	87	90.8	60.47 ± 9.83
Controls without COPD and CI					60	68.33	58.15 ± 9.8

Note. Studies included in the meta-analysis by Yohannes *et al.* [17] are not included in this table. PR: pulmonary rehabilitation; COPD: chronic obstructive pulmonary disease; CI: cognitive impairment; NETT: National Emphysema Treatment Trial; GOLD: Global Initiative for Chronic Obstructive Lung Disease; SD: standard deviation; MAAS: Maastricht Aging Study; MMSE: Mini-Mental State Examination; MoCA: Montreal Cognitive Assessment; TMTB: Trail Making Test, part B.

to PR was below the fifth percentile of a normal reference group, and only 38.1% scored higher than the median [20]. This may be related to the fact that patients referred for PR generally have moderate to advanced disease. Roncero *et al.* showed CI in 39.4% of stable COPD patients. This study was large ($N = 940$), but it only assessed cognition using the Mini-Mental State Examination (MMSE) [21], which is useful as a screening tool but not as a diagnostic tool [22]. Samareh Fekri *et al.* likewise administered the MMSE to 87 COPD patients and 60 age- and gender-matched individuals. MCI was present in 44.8% of patients with COPD and moderate CI in 6.9%, compared to 33.3% and 3.3%, respectively, in controls [23]. It is not reported whether these percentages differ significantly, but the mean MMSE score in the COPD group was significantly lower than in the control group (22.51 ± 2.4 versus 23.63 ± 2.8 , respectively).

Lopez-Torres *et al.* investigated cognition during hospitalization for an exacerbation, at discharge and after return to a stable state [25]. Cognitive functioning measured by MoCA scores increased significantly from hospitalization to discharge and decreased again from discharge to stable state, but to a higher level than at hospitalization.

In summary, a wide range of prevalences is reported for CI in COPD. The heterogeneity of applied cognitive tests and cut-off points to define CI, as well as diverse study populations (community-dwelling, pulmonary rehabilitation, hospitalized patients, etc.) likely contributes to this wide range.

3.1.2. Longitudinal studies

Future research using longitudinal designs may elucidate the development of CI in COPD over several years and the influence of disease progression and other factors in different disease stages. The longitudinal studies already conducted have shown some interesting results. A self-reported diagnosis of COPD in midlife increased the risk of developing CI later in life (odds ratio 1.85, 95% CI 1.05–3.28), but COPD diagnosed later in life was non-significantly inversely related to CI (odds ratio 0.30, 95% CI 0.08–1.24) [26]. This surprising result might be explained by survival bias rather than the effects of COPD itself [26]. In a recent study, 32.6% of patients taking part in the National Emphysema Treatment Trial (NETT) were impaired on part B of the Trail Making Test (TMT) at baseline [27]. This test measures task switching, which is part of executive functioning. No prevalence estimates were given for subsequent time points, but TMT-B performance was virtually unchanged over the 3-year follow-up. Most remarkably, the sample could be distinguished into four clusters based on their trajectories of cognitive development over 3 years. One cluster (35.5%) had low baseline TMT-B scores and improving scores over time, the second (39.7%) had low baseline and worsening scores, the third (18.2%) had high baseline and worsening scores, and the fourth (6.5%) had high baseline and improving scores.

Table 2.

Study (First author, year)	Cognitive tests used	Criteria/cut-off for CI	% MCI	% ACI	Misc. methodological strengths/weaknesses
Cleutjens, 2017a	Comprehensive neuropsychological test battery	Score less than 1SD below age-, gender- and education-specific mean of the MAAS study [24] on 2 subtests or more		56.7% (general CI)	Comprehensive cognitive test battery is used, and cognitive scores are split into different domains. But composite scores are made.
Cleutjens, 2017b	Comprehensive neuropsychological test battery	Score less than 1SD below age-, gender- and education-specific mean of the MAAS study [24] on 2 subtests or more		13.3% (general CI) 41.5%	Comprehensive cognitive test battery is used, but composite scores are made.
Cleutjens, 2017c	MMSE; comprehensive neuropsychological test battery	MMSE < 24; Score less than 1SD below age-, gender- and education-specific mean of the MAAS study on 2 subtests or more		MMSE: 5.7% Comprehensive neuropsychological test battery: 38.2%	Comprehensive cognitive test battery is used, and cognitive scores are split into different domains.
Lopez-Torres, 2016	MoCA	MoCA < 20		At exacerbation: 48.3% At discharge: 23.6% In stable condition: 36.3%	Different numbers given for gender and age distribution in table compared with figures. Different MoCA versions were used in order to eliminate practice effects; patients with dementia were excluded from participation.
Pierobon, 2017 Park, 2018	MoCA, MMSE TMT-B	MoCA performance within the bottom 5% of the population Score > 1.5 SD above the normative mean of the current study [134.666 for those with < 12 years of education; 81.095 for those with > 12 years of education] MMSE < 27	9.5% 32.6%		Patients with an MMSE of < 18.3 were excluded. In- and exclusion criteria for the NETT trial did not specifically have cognitive research in mind: for instance neurological disorders or medication which could affect cognition were not excluded.
Roncero, 2016 Samareh Fekri, 2017	MMSE MMSE	Mild: MMSE 19–23 Moderate: MMSE 10–19 Severe: MMSE < 10	39.4% 44.82% 33.33%	6.89% had moderate CI 3.33% had moderate CI	Unconventional cut-offs for CI; skewed gender distribution (91% men in the COPD group); many participants had an opium addiction or history of baking in traditional furnaces; in the control group, a non-smoking history was three times more common than in the COPD group (36.7% vs 12.6%)

3.2. Cerebral abnormalities

CI is associated with global and/or specific cerebral abnormalities, and many studies have found structural or functional abnormalities in patients with COPD, along with elevated serum levels of S100B, a putative marker for brain damage [28].

Cortical degeneration [29–32], increased occurrence of small vessel disease [33] or abnormal functional activation on a global level is uncommon in COPD, with a few exceptions. Two studies found overall increased white matter (WM) lesion volumes and decreased WM integrity [30,31], and cortical thickness and volume were globally reduced in patients who were hospitalized for 30–45 days following an exacerbation [34].

Regional changes are more common. Gray matter (GM) was found to be decreased in many brain regions in both hemispheres, among others in the dorsolateral prefrontal cortex [34], which is involved in higher functions and working memory [35]; different areas involved in visuospatial processing [36]; the frontal cortex; and limbic and paralimbic structures [15,29], which are mainly involved in emotion processing and memory [37]. Disease duration was inversely related to GM volume in various, mainly subcortical, regions [12,29], but not in others, including the hippocampus and amygdala [29].

Reduced WM integrity in the superior and middle frontal gyri and right occipital subcortical WM was shown in patients with moderate COPD [32]. WM integrity was more reduced in the bilateral frontal subcortical areas, right temporal lobe and pons in severe compared to moderate COPD. Patients with an acute exacerbation who had been hospitalized for several weeks also showed reduced WM integrity compared to healthy controls in various (para)limbic regions [12]. However, Cleutjens *et al.* [33] showed that cognitively weak and cognitively strong patients with COPD had equal amounts of WM hyperintensities (WMH).

Two studies investigated the relation between lung function and brain volume in healthy elderly. One study reported a significant correlation between forced expiratory volume in 1 second (FEV₁) and overall brain atrophy and ventricle-to-brain ratio in men but not in women [38]. The FEV₁/forced vital capacity (FVC) ratio was correlated with WMH in the sample as a whole. Participants with and without chronic respiratory disease did not differ on any clinical or brain imaging parameter. Moreover, no control variables were included. The second study only showed a significant positive relationship between FEV₁ and cerebellar WM volume, but no generalized cortical degeneration [39].

The hippocampus is interesting as it is vital in memory formation and learning, and only one of the two regions to display neurogenesis in the adult human brain [40]. As such, decreased hippocampal volume could also indicate abnormalities in brain plasticity in patients with COPD, but findings are mixed. In one study, hippocampal volume was decreased in COPD compared to healthy controls and its size was related to partial oxygen pressure and oxygen saturation [41]. Hippocampal volume did not differ between patients with mild-to-moderate COPD and those with severe COPD [41]. In another study, however, hippocampal volume was not significantly different between patients with COPD and controls [42],

and it has also been shown to not differ between cognitively strong and cognitively weak patients with COPD [33].

Functional abnormalities were reported in the left precentral and postcentral gyri and the left caudate nucleus when comparing patients with COPD with controls matched on age, sex, and education [14]. Evidence on resting state network and default mode network activity is mixed. These networks are distinct from others because their activity increases when the brain is not engaged with other tasks [43]. Their increased activation could hinder cognition by interfering with task-related activity. One study found increased resting-state network activity in patients with COPD compared to healthy controls, but this result was not significant anymore after controlling for oxygen saturation [14]. Another study also found increased default network activation in patients with moderate COPD but decreased activation in those with severe COPD [44]. This result might reflect a compensatory response to damage inflicted by factors associated with COPD, and this response might be strongest in patients with moderate COPD [44].

The structural and functional abnormalities discussed above reflect a gradual influence of COPD on the brain. However, COPD can also heighten the risk of more acute events, such as stroke. This is likely due to high levels of systemic inflammation and oxidative stress, possibly as a result of smoking, leading to endothelial dysfunction, decreased vascular reactivity, thickening of the carotid artery wall and atherosclerotic plaque rupture [45]. An elevated risk of stroke in patients with COPD was found in several studies (hazard ratios [HRs] 1.09 [CI95 0.91–1.31] and 1.24 [CI95 1.19–1.28] [46,47]) and meta-analyses (HRs 1.30 [CI95 1.09–2.09] [48,49]). The significance in the latter study was probably due to the large sample size ($N = 132,017$ versus 1,566 in the former). HRs are roughly equal for the ischemic, hemorrhagic, intracerebral, and subarachnoid hemorrhagic subtypes. However, in the weeks after an acute exacerbation, the HR increased to 6.66 (CI95 2.42–18.20) [46].

In conclusion, patients with COPD show an increased prevalence of many different types of cerebral abnormalities, compared to healthy controls. Patients with COPD have reduced gray and WM volume in various brain areas and WM integrity is compromised. It is still equivocal whether hippocampal volume is decreased in patients with COPD. There is evidence for abnormal functional activation, particularly in the resting state and default mode networks. The abnormalities are spread throughout the brain rather than concentrated in one or some areas. This could possibly explain the diffuse pattern of CI found in COPD.

4. CI and health outcomes in COPD

CI has a wide range of adverse effects on self-management skills and other health outcomes in patients with COPD (see Figure 3).

4.1. Self-management skills

Self-management skills are of major importance for patients with COPD. Symptoms may vary from day to day and increased symptoms may be caused by exacerbations. Patients need to recognize and act upon these exacerbations in an adequate manner [50]. Moreover, patients need to adhere to their

Figure 3. The possible relationships between cognitive impairment and clinical outcomes. Dotted lines represent conflicting literature concerning the relationship.

medication and need to adopt a healthy lifestyle, including a healthy diet and physical activity. Smokers need to quit smoking. This often requires a behavior change, which poses a demand on cognitive functioning [50]. It is therefore feasible that CI limits the ability to cope with the daily challenges of living with COPD.

A recent systematic review revealed that there was just one study in which the impact of CI on self-management skills in patients with COPD was investigated [51]. This particular study, including 100 participants with COPD, showed no relationship between cognitive functioning assessed with the MoCA and overall self-management abilities, as measured by the Self Management Ability Score 30 (SMAS30). SMAS30 assesses the following: taking initiatives, investment behavior, variety, multi-functionality, self-efficacy, and positive frame of mind. Moreover, living alone affected the interaction between cognitive functioning and self-management abilities [52]. In fact, only among patients who lived alone, better cognitive functioning was related to lower self-management abilities [52]. Emotional intelligence (defined as the capacity to understand and manage personal thoughts and feelings, as well as to positively influence interpersonal communication and social well-being), however, seems to be related to self-management abilities in COPD [53].

Meek *et al.* [54] showed a relationship between MMSE scores and the ability to accurately recall severity of fatigue and dyspnea in the previous two weeks. It is reasonable to assume that this might impact on the ability to recognize and act upon symptoms of an exacerbation, but the exact relationship remains unknown.

The relationship between CI and inhaler competency is well-known [51]. An MMSE score of 23–24 points or less is predictive of poor inhaler technique, as are impaired executive functioning and impaired praxis. While some inhalers may be more difficult to use than others, recognizing CI is of major importance when prescribing inhaler devices as well as providing instructions to use them [51]. Some studies suggest Turbhalers might be easier to use for patients with CI than metered dose inhalers

[51,55]. To our knowledge, however, there are no recommendations specifically on inhaler use for COPD patients with CI. Nevertheless, inhaler competency is a major consideration when prescribing inhalers and should be checked regularly.

Brega *et al.* [56] showed that older persons with impaired executive functioning were less likely to quit smoking than those with normal executive functioning. However, recent data did not confirm the relationship between executive cognitive dysfunction and smoking cessation [57]. Moreover, another study even showed that persons over 75 years of age who quit smoking had lower cognitive functioning than persons who continued smoking [58]. Differences in findings about the relationship between smoking and cognition might be explained by the fact that patients in the last study were older and different methods were used to assess cognitive functioning. Cleutjens *et al.* did not find a statistically significant difference in smoking status between patients with COPD entering PR with or without CI [19]. Therefore, whether and to what extent CI limits the ability of patients with COPD to quit smoking remains unclear.

4.2. Health outcomes

CI seems related to functional exercise capacity as measured by 6-minute walking distance [59,60]. Nevertheless, this was not confirmed among patients entering PR [19] or during an exacerbation [59].

Cleutjens *et al.* showed that the response after completion of a PR program was similar in patients with CI compared to those without [61]. However, patients with CI were more likely to drop out compared to those without CI (23.3% versus 10.3%, respectively). Therefore, timely recognition of CI in patients entering PR seems paramount.

Several studies showed an inverse relationship between CI and HRQoL as assessed with the COPD Assessment Test [21,60], the EuroQoL-5 dimensions questionnaire [21] or St

George's Respiratory Questionnaire [22]. Then again, other studies did not confirm this relationship [19,62].

The systematic review of Baird *et al.* included four studies exploring the relationship between CI and disability and showed that CI is related to impairment in basic activities of daily living, instrumental activities of daily living, work, and social activities [51]. Martinez *et al.* found that COPD and CI have independent but additive effects on disability [63].

The co-existence of CI and COPD is associated with a more than fourfold increased risk of hospitalization for respiratory-related illnesses and a 34% higher risk of all-cause hospitalization compared to healthy controls, after controlling for various sociodemographic variables, smoking status and comorbidities [64]. Moreover, CI seems to be related to an increased length of hospitalization [22]. Data from the NETT trial did not show an association between impairment in executive functioning and frequency of hospitalization [65].

A study including stable patients with COPD even showed that drawing impairment predicted increased mortality risk [66]. Nevertheless, Yohannes *et al.* found that MMSE scores did not predict 1-year all-cause mortality [67]. Moreover, only a modest association was found between executive function and survival in the NETT trial [65].

In conclusion, CI may negatively impact self-management and health outcomes in COPD, but the current literature is conflicting and many questions remain. The conflicting literature may be explained by different methods used to assess cognitive functioning and criteria used to define CI. Moreover, there were major differences between the studied populations. The complex cause–effect relationships also make this field very challenging. COPD may influence self-management skills, but poor self-management in turn also worsens COPD disease progression, thereby creating a vicious cycle.

5. Determinants of COPD-induced cognitive impairment

Factors such as hypoxemia, hypercapnia, inflammation, and lifestyle factors may all contribute to structural and functional cerebral abnormalities and CI. Any individual factor probably does not explain a significant amount of CI, but their synergistic effects may be large [11,68].

5.1. Hypoxemia and hypercapnia

Hypoxemia and hypercapnia are hallmarks of severe COPD [69] which can also negatively affect cognition [70,71]. Hypoxemia alters the microenvironment around neurons [72] and induces impairments in spontaneous and task-stimulated neuronal activity [73,74]. Hypoxemia might underlie decreases in GM density [12,15], and mild hypercapnia decreases functional connectivity in almost all brain lobes [75]. The exact mechanisms through which this happens are still unclear [75]. Diminished vasodilatation in response to hypoxemia or hypercapnia in patients with COPD might be one [76].

5.2. Inflammation

Multiple lines of evidence indicate that systemic inflammation might underlie CI in COPD. Low-grade systemic inflammation is linked to decreased cognition in other conditions including obesity [77,78] and metabolic syndrome [79,80]. In the general population c-reactive protein (CRP) and interleukin-6 levels were related to global cognition and executive functioning, whereas α 1-antichymotrypsin was not [81]. MoCA scores have been found to be negatively correlated with CRP, fibrinogen, and erythrocyte sedimentation rate levels [82]. The relationship between inflammation and cognition in stable COPD has not been thoroughly investigated yet. Next to low-grade systemic inflammation, patients with COPD may experience periods of an enhanced systemic inflammatory response related to disease exacerbations that will be discussed later.

5.3. Respiratory medication

Long-acting beta-adrenoreceptor agonists (LABA), long-acting muscarinic antagonists (LAMA) and inhaled corticosteroids are frequently prescribed to patients with COPD [1].

Some literature has associated anticholinergic use with increased risk of MCI [83] and dementia [83–85], and faster cognitive decline [86]. However, participants in these studies used systemic rather than inhaled medication. Inhaled medication is much more targeted and will therefore have much less systemic effects. For example, tiotropium cannot cross the blood-brain barrier [87] which might suggest no or limited effect on cognitive functioning. However, no studies have investigated the effects of tiotropium on cognition yet.

The effects of corticosteroids or glucocorticoids (GC) on cognition have not been investigated in patients with COPD yet either. In general, mildly elevated GC levels improve cognition [88], but long-term administration can cause 'steroid dementia', characterized by impairments in episodic, declarative and working memory and executive function, and associated hippocampal and prefrontal dysfunction [89]. Steroid dementia can appear within weeks of commencing GC treatment and is largely reversible upon its termination, although impairments can remain for years after termination [89,90].

It is doubtful whether steroid dementia is a real risk in COPD. The recommended dose and duration for patients with an acute exacerbation (30–40 mg of prednisone daily for 7–14 days, where 5 days may be equally effective [91]) are much lower and shorter than those reported to cause steroid dementia (i.e., 60 mg/day for 7 months [90] or 40–60 mg/day for 37 days [92]).

In conclusion, to date, evidence that respiratory medication can contribute to impaired cognition in patients with COPD is lacking.

5.4. Exacerbations

During acute exacerbations, the above-mentioned determinants intensify and converge. Interestingly, exacerbations

have an additional detrimental effect on cognition [22,82,93,94]. During acute exacerbations, levels of inflammation and cognitive functioning are inversely related [95], and as recovery from exacerbation-related CI seems very slow to non-existent, it can be speculated that regular COPD exacerbations can trigger a stepwise decrease in cognition. One study found no improvement in the 3 months after an exacerbation [22]. However, because these patients were not cognitively tested prior to the exacerbation, it cannot be determined whether the exacerbation actually affected cognition in this study.

5.5. Comorbidities

COPD often presents with comorbid conditions such as obstructive sleep apnea (OSA), depression and chronic heart failure (CHF), and a recent systematic review reported an increased risk prevalence of the metabolic syndrome in COPD compared to matched controls [96].

OSA contributes to decreased arterial oxygen saturation [97], causes sleep fragmentation and cortical and sympathetic arousal [97,98], and affects attention, memory, psychomotor speed, visuospatial abilities, constructional abilities, executive functions, and language abilities [97,99]. Hypoxemia, a shared component between OSA and advanced COPD, might underlie the cognitive deficits apparent in both diseases, namely attention, memory, executive function, psychomotor function, and language abilities [99].

Depression is associated with decreased cognitive functioning [100] in COPD, but it probably only predicts 1–2% of the variation in cognition [3]. A study investigating cognitive bias in patients with COPD and healthy controls with and without depression revealed that depressed patients with COPD showed a comparable pattern of bias compared to depressed healthy controls, whereas never-depressed patients showed much less bias [101]. In conclusion, the influence of concurrent COPD and depression on cognition is still equivocal.

Many patients with COPD also suffer from CHF, and *vice versa* [17]. The prevalence of CI in CHF is largely unknown, as prevalence estimates between 13.5% and 80% have been reported [17]. CHF and COPD might have additive effects on cognition. Moreover, COPD and CHF are both associated with a high prevalence of cerebrovascular diseases, which could lead to chronic cerebral hypoxia, impaired brain perfusion and ultimately brain damage and cognitive impairment [17]. Furthermore, etiological similarities, such as cigarette smoking, may lead to a common set of symptoms, including CI [17].

Metabolic syndrome (MetS) is a cluster of metabolic risk factors, such as central obesity, dyslipidemia, hyperglycemia and dyslipidemia [96], with a prevalence of 34% in patients with COPD [96]. MetS is strongly related to the risk of developing type 2 diabetes and cardiovascular disease [96] and has also been shown to have a deleterious influence on cognition [102,103]. However, some research also suggests that certain components of MetS have a larger effect than others [104,105]. It is yet unclear what the relative contribution of each of the components of MetS on cognition is.

5.6. Smoking

Smoking is one of the largest risk factors for developing lung cancer or COPD, and it affects cognition in multiple ways. Firstly, it increases carbon monoxide and carbon dioxide levels in the blood, causing hypercapnia [106] and hypoxemia [107], respectively. Secondly, cigarette smoke contains many neurotoxic components, such as cadmium, nitric oxide and lead [108]. Thirdly, the many free radicals in cigarette smoke are neurotoxic [109]. And finally, chronic nicotine administration increases tau phosphorylation, a key component of Alzheimer's disease pathophysiology [108], and induced free radical production and depleted antioxidant levels in a rat model [110]. Ultimately, all of these components cause decreased GM and WM volume and connectivity, and impair cognition [111–113].

Only one study investigated the influence of smoking on CI specifically in patients with COPD [114]. Cognitive performance of patients with COPD was comparable to that of smokers, but both were significantly worse compared to normal reference values. The number of pack-years and the duration of abstinence of the past smokers, consisting almost two-thirds of the sample, was not reported. Therefore, it cannot be determined with certainty to which degree smoking affects cognition beyond the effects of COPD. In general, smoking *per se* contributes to cognitive dysfunction, but there is also evidence of a relationship between impaired lung function and cognition independent of smoking [3,115].

5.7. Dietary insufficiencies

Diet and nutritional habits significantly impact on brain fitness, mental and cognitive health throughout life [116,117]. The relative abundance of specific dietary nutrients, depending on intake, bioavailability and metabolism, affects mental health and cognitive ability via direct and indirect mechanisms that modulate neuronal function and synaptic plasticity [118]. Chronic stress has been shown to negatively impact on brain plasticity and cognitive performance, for instance through the harmful effects of cortisol [119–121] and poor dietary habits are hypothesized to correlate with heightened stress reactivity and susceptibility [122] and greater cognitive decline in elderly [123]. A healthy diet, rich in polyphenols, B vitamins, polyunsaturated fatty acids, and dietary fibers exert favorable effects on cognitive performance, stress reactivity, and neuroinflammation [118,124]. Unintended weight loss and muscle wasting are common in advanced COPD, but specific nutritional deficiencies that could affect cognition have received limited attention to date. However, next to disease severity, Collins *et al.* recently highlighted in a UK COPD population the importance of deprivation on malnutrition risk [125]. An Australian study reported, next to low muscle mass, a high prevalence of deficiencies in vitamin D, vitamin B12 and iron in patients with COPD hospitalized with an acute exacerbation [126]. A Dutch study investigating patients eligible for PR reported that vitamin D and calcium intake were below the recommended levels in more than 75% of patients, whereas vitamin A, C and E intakes were below the recommended levels in over one-third of patients [127]. No studies have yet investigated

the relationship between nutritional status or dietary pattern and cognitive performance in COPD.

5.8. Inactive lifestyle

Higher levels of physical activity are associated with a reduced risk of cognitive decline and dementia [128]. However, disease-related factors such as dyspnea and muscular metabolic abnormalities make it hard for many patients with COPD to be physically active. One systematic review found a mean daily step count of 2,237 [129], which is far less than the threshold for a low active (5,000 steps) or active lifestyle (10,000 steps) indicated by the same authors [129]. Low physical activity levels and a sedentary lifestyle negatively impact on cognition in the general population [130,131], and as such may contribute to CI in COPD as well.

Overall, disease-specific as well as lifestyle factors may contribute to the development of CI in COPD, but the relative potential synergistic contributions of the individual factors are yet unclear.

6. Possible future interventions

6.1. Cognitive training

Cognitive training can improve cognitive functioning in healthy elderly adults [132,133], and can also improve some cognitive domains in those with MCI [132]. Research into cognitive training specifically for patients with COPD is scarce. One trial attempted to ameliorate cognition in hypoxemic patients with COPD through an intervention aimed at improving attention, learning, and logical-deductive thinking [134]. During the first 2 weeks, the intervention group received group cognitive training, in the four weeks thereafter they received individual training, followed by home assignments two times per week. Booster sessions took place after 3 and 5 months. The control group received usual care and no cognitive training. Some cognitive domains improved in both the intervention and placebo group, but the intervention had no additional effect on cognition.

6.2. Exercise training

Exercise can improve cognition through multiple pathways. It causes an increase in cerebral blood flow [38] and levels of cerebral growth factors such as brain-derived neurotrophic factor [135] and insulin growth factor-1 [136]. These growth factors are involved in many functions which are important for cognition. They influence the rate of differentiation and apoptosis of cerebral cells [137] and regulate long-term potentiation [138] and hippocampal neurogenesis [137]. Multiple previous studies have shown the benefit of exercise on cognition in COPD patients [139,140], and in the study by Park *et al.* the 6-minute walking distance was the only potentially modifiable variable that was related to worsening cognitive functioning over time [27]. The question remains, however, whether these improvements consolidate into the longer term if exercise is discontinued [11].

6.3. Smoking cessation

Given the deleterious influences of smoking on cognition, it is unsurprising that smoking cessation is beneficial. However, its effects on cognitive functioning have only been assessed in the general population. It appears that the number of pack-years negatively affects cognitive functioning, but also that cognitive functioning improves with longer duration of abstinence [141]. This implies that abstinence pays off at any age, with the largest benefits coming to those who stop the earliest. Future research should further investigate the effects of smoking cessation on cognition in COPD in more detail.

6.4. Dietary intervention

Dietary intervention may imply adopting a different dietary pattern or supplementing the habitual diet with specific nutrients. The Mediterranean diet, the Dietary Approach to Stop Hypertension (DASH) diet and the Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) diet have been proposed as beneficial to cognition [142–144]. Drastic dietary changes, however, are not likely to be feasible for patients with advanced COPD.

These interventions imply that CI in COPD is not something that patients have to passively undergo, but can be readily applied in daily life. However, more research is needed to assess the feasibility and efficacy of the individual interventions or multimodalities thereof.

7. Conclusion

CI in patients with COPD is a problem with a high prevalence and large consequences, yet it is still under-recognized and under-investigated. More research aimed at unraveling the etiology and appropriate interventions to diminish cognitive decline or treat CI in patients with COPD is needed to benefit the patients as well as their loved ones.

Caregivers should pay more attention to potential CI in their patients, as CI may have large consequences on self-management and health outcomes. In a clinical context, administering a brief screening tool may help in identifying patients who need referral to a specialist for further investigation. These patients also need more time and attention, for instance, while making sure they understand how to properly use their medication.

8. Expert commentary

Technical developments in the field of cognitive neuroscience enable more detailed insight in the *pathophysiology* of CI in COPD. Increasing magnetic resonance imaging resolution allows a more detailed picture of the brain, techniques such as diffusion tensor imaging allow focusing specifically on WM instead of the brain as a whole, and shorter and more effective scanning protocols can make brain imaging more accessible and affordable.

Investigating novel research directions might also be worthwhile. For instance, the synthesis and proper functioning of many neurotransmitters, including the catecholamines, glutamate, aspartate, and perhaps most importantly acetylcholine (as it is widely available in the brain but also the most

important neurotransmitter in the airways) depend on oxygen availability [145]. Hypoxia-based neurotransmitter abnormalities might therefore constitute a third type of cerebral abnormality contributing to CI, next to structural and functional abnormalities. However, this has received scarce research attention to date in the general population, and especially in COPD.

Longitudinal studies are essential for understanding the *causes and consequences* of CI in COPD. They can elucidate the development of cognitive decline in COPD in relation to the development of other potentially relevant variables such as impaired lung function, hypoxia or inflammation. In this way, the relative contributions of disease- and aging-related factors can also be further disentangled.

Interesting *treatment options* for CI in COPD include the potential role of specific nutrients in ameliorating cognition. The Mediterranean diet, which is characterized by a high intake of plant-based foods, moderate-to-high fish and seafood consumption and scarce use of dairy products and meat [142], has earlier been shown to improve cognition in a randomized controlled trial [142]. Furthermore, polyunsaturated fatty acids and polyphenols can ameliorate cognition and have a positive effect on various neurobiological processes [146]. Also, testing potential synergistic effects of combinations of interventions could be worthwhile, such as exercise training and cognitive training.

An important prerequisite for all the above research questions is the choice of the right cognitive test instruments. Often applied screening tools such as the MMSE or MoCA can be useful in a clinical setting to identify patients in need of further neuropsychological assessment and therapy, but cannot give a detailed overview of the exact nature of a person's deficits. Larger, well-defined and evidence-based test batteries are essential in order to get a comprehensive overview of a person's neuropsychological functioning [147].

9. Five-year view

In conclusion, it is important to further investigate the pathophysiology, causes and consequences of CI in COPD in the next 5 years, and to develop tailored intervention strategies. Developments in the fields of cognitive neuroscience and neuropsychology will enable a more detailed picture of the pathophysiology of CI in COPD. Longitudinal studies can pinpoint its determinants and identify its consequences, and much work remains to be done in finding (the most) effective treatments.

Key issues

- Cognitive impairment is an important extra-pulmonary feature of COPD
- A wide range of cognitive functions are affected in patients with COPD, such as memory and various executive functions
- Cognitive impairment has a high prevalence in patients with COPD and is more common in patients with COPD than in age-matched controls.
- Many factors can contribute to the development of brain damage and cognitive impairment in COPD, such as

smoking, hypoxemia, inflammation, different comorbidities, dietary insufficiencies, medication use and lack of activity.

- Cognitive impairment has large negative consequences on health outcomes of patients with COPD, including hospitalization.
- Interventions such as exercise training, smoking cessation and dietary improvement are promising to prevent or treat (mild) cognitive impairment.

Future research should focus on investigating aspects such as the longitudinal development of cognitive impairment in COPD and the efficacy of various interventions to prevent and treat it.

Funding

This study was supported by grants from the Netherlands Lung Foundation (grant 3.4.09.003) and ZonMW (JPI-HDHL 'Ambrosiac' grant).

Declaration of interest

The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Reviewer Disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

ORCID

Martijn van Beers <http://orcid.org/0000-0001-6193-3160>

References

Papers of special note have been highlighted as either of interest (*) or of considerable interest () to readers.**

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease (2018 Report). Agusti A, Vogelmeier C, editors. 2018.
2. Cavaillès A, Brinchault-Rabin G, Dixmier A, et al. Comorbidities of COPD. *Eur Respir Rev*. 2013;22:454–475.
3. Dodd JW, Getov SV, Jones PW. Cognitive function in COPD. *Eur Respir J*. 2010;35:913–922.
- Gives a relatively comprehensive overview of cognitive impairment in COPD and relevant issues relating to it.
4. Cleutjens FA, Janssen DJ, Ponds RW, et al. Cognitive-pulmonary disease. *Biomed Res Int*. 2014;697825.
5. Lezak MD, Howieson DB, Bigler ED, et al. Neuropsychological assessment. 5th. New York, NY: Oxford University Press; 2012.
6. Franz EA, Gillett G. John Hughlings Jackson's evolutionary neurology: a unifying framework for cognitive neuroscience. *Brain*. 2011;134(10):3114–3120.
7. Diamond A. Executive functions. *Annu Rev Psychol*. 2013;64:135–168.
8. Kolb B, Whishaw IQ. An introduction to brain and behavior. 3rd ed. New York, NY: Worth Publishers; 2011.
9. Petersen RC. Mild cognitive impairment. *Continuum*. 2016;22(2):404–418.
10. Belleville S, Fouquet C, Hudon C, et al. Neuropsychological measures that predict progression from mild cognitive impairment to Alzheimer's type dementia in older adults: a systematic review and meta-analysis. *Neuropsychol Rev*. 2017;27(4):328–353.

11. Ouellette DR, Lavoie KL. Recognition, diagnosis and treatment of cognitive and psychiatric disorders in patients with COPD. *Int J COPD*. 2017;12:639–650.
- **Gives a relatively comprehensive overview of cognitive impairment in COPD and relevant issues relating to it.**
12. Zhang H, Wang X, Lin J, et al. Grey and white matter abnormalities in chronic obstructive pulmonary disease: a case-control study. *BMJ Open*. 2012;2:e000844.
13. Schou L, Ostergaard B, Rasmussen LS, et al. Cognitive dysfunction in patients with chronic obstructive pulmonary disease - a systematic review. *Respir Med*. 2012;106:1071–1081.
14. Zhang J, Chen J, Yu Q, et al. Alteration of spontaneous brain activity in COPD patients. *Int J COPD*. 2016;11:1713–1719.
15. Zhang H, Wang X, Lin J, et al. Reduced regional gray matter volume in patients with chronic obstructive pulmonary disease: a voxel-based morphometry study. *Am J Neuroradiology*. 2013;34(2):334–339.
16. Andrianopoulos V, Gloeckl R, Vogiatzis I, et al. Cognitive impairment in COPD: should cognitive evaluation be part of respiratory assessment? *Breathe*. 2017;13(1):e1–e9.
17. Yohannes AM, Chen W, Moga AM, et al. Cognitive impairment in chronic obstructive pulmonary disease and chronic heart failure: a systematic review and meta-analysis of observational studies. *JAMDA*. 2017;18:451.e1–451.e11.
18. Cleutjens FA, Franssen FM, Spruit MA, et al. Domain-specific cognitive impairment in patients with COPD and control subjects. *Int J COPD*. 2016;12:1–11.
19. Cleutjens FA, Spruit MA, Ponds RW, et al. Cognitive impairment and clinical characteristics in patients with chronic obstructive pulmonary disease. *Chron Respir Dis*. 2018;15(2):91–102.
20. Pierobon A, Bottelli ES, Ranzini L, et al. COPD patients' self-reported adherence, psychosocial factors and mild cognitive impairment in pulmonary rehabilitation. *Int J COPD*. 2017;12:2059–2067.
21. Roncero C, Campuzano AI, Quintano JA, et al. Cognitive status among patients with chronic obstructive pulmonary disease. *Int J COPD*. 2016;11:543–551.
22. Dodd JW, Charlton RA, Van den Broek MD, et al. Cognitive dysfunction in patients hospitalized with acute exacerbation of COPD. *Chest*. 2013;144:119–127.
- **The only paper to date specifically investigating cognitive dysfunctioning in patients with COPD suffering from an exacerbation.**
23. Fekri MS, Hashemi-Bajgani S-M, Naghibzadeh-Tahami A, et al. Cognitive impairment among patients with chronic obstructive pulmonary disease compared to normal individuals. *Tanaffos*. 2017;16(1):34–39.
24. Jolles J, Van Boxtel MPJ, Ponds RW, et al. The Maastricht Aging Study (MAAS): the longitudinal perspective of cognitive aging. *Tijdschr Gerontol Geriatr*. 1998;29(3):120–129.
25. López-Torres I, Valenza MC, Torres-Sánchez I, et al. Changes in cognitive status in COPD patients across clinical stages. *COPD*. 2016;13(3):327–332.
26. Rusanen M, Ngandu T, Laatikainen T, et al. Chronic obstructive pulmonary disease and asthma and the risk of mild cognitive impairment and dementia: a population based CAIDE study. *Curr Alzheimer Res*. 2013;10:549–555.
27. Park SK. Trajectories of change in cognitive function in people with COPD. *J Clin Nurs*. 2018;27:1529–1542.
- **One of the few papers to date investigating the longitudinal development of cognitive impairment in COPD.**
28. Korfias S, Stranjalis G, Papadimitrou A, et al. Serum S-100B protein as a biochemical marker of brain injury: a review of current concepts. *Curr Med Chem*. 2006;13(30):3719–3731.
29. Esser RW, Stoeckel MC, Kirsten A, et al. Structural brain changes in patients with COPD. *Chest*. 2016;149(2):426–434.
30. Spilling CA, Jones PW, Dodd JW, et al. White matter lesions characterise brain involvement in moderate to severe chronic obstructive pulmonary disease, but cerebral atrophy does not. *BMC Pulm Med*. 2017;17:92.
- **A recent paper investigating both gray and white matter damage in COPD.**
31. Dodd JW, Chung AW, Van den Broek MD, et al. Brain structure and function in chronic obstructive pulmonary disease - a multimodal cranial magnetic resonance imaging study. *Am J Respir Crit Care Med*. 2012;186(3):240–245.
32. Ryu C-W, Jahng G-H, Choi CW, et al. Microstructural change of the brain in chronic obstructive pulmonary disease: a voxel-based investigation by MRI. *J Chronic Obstructive Pulm Dis*. 2013;10:357–366.
33. Cleutjens FA, Ponds RW, Spruit MA, et al. The relationship between cerebral small vessel disease, hippocampal volume and cognitive functioning in patients with COPD: an MRI study. *Front Aging Neurosci*. 2017;9:88.
34. Chen J, Lin I-T, Zhang H, et al. Reduced cortical thickness, surface area in patients with chronic obstructive pulmonary disease: a surface-based morphometry and neuropsychological study. *Brain Imaging Behav*. 2016;10:464–476.
35. Barbey AK, Koenigs M, Grafman J. Dorsolateral prefrontal contributions to human working memory. *Cortex*. 2013;49:1195–1205.
36. Wang C, Ding Y, Shen B, et al. Altered gray matter volume in stable chronic obstructive pulmonary disease with subclinical cognitive impairment: an exploratory study. *Neurotox Res*. 2017;31(4):453–463.
37. Lövsblad KO, Schaller K, Vargas MI. The fornix and limbic system. *Semin Ultrasound CT MR*. 2014;35(5):459–473.
38. Sachdev PS, Anstey KJ, Parslow RA, et al. Pulmonary function, cognitive impairment and brain atrophy in a middle-aged community sample. *Dement Geriatr Cogn Disord*. 2006;21:300–308.
39. Taki Y, Kinomura S, Ebihara S, et al. Correlation between pulmonary function and brain volume in healthy elderly subjects. *Neuroradiology*. 2013;55(6):689–695.
40. Poulouse SM, Miller MG, Scott T, et al. Nutritional factors affecting adult neurogenesis and cognitive function. *Adv Nutr*. 2017;8:804–811.
41. Li J, Fei GH. The unique alterations of hippocampus and cognitive impairment in chronic obstructive pulmonary disease. *Respir Res*. 2013;14:140.
42. Borson S, Scanlan J, Friedman S, et al. Modeling the impact of COPD on the brain. *Int J COPD*. 2008;3(3):429–434.
43. Fox MD, Snyder AZ, Vincent JL, et al. The human brain is intrinsically organized into dynamic, anticorrelated functional networks. *PNAS*. 2005;102(27):9673–9678.
44. Hu X, Wang H, Tu Y, et al. Alterations of the default mode network and cognitive impairments in patients with chronic obstructive pulmonary disease. *Int J COPD*. 2018;13:519–528.
45. Leung JM, Sin DD. Chronic obstructive pulmonary disease and stroke: strange bedfellows. *Am J Respir Crit Care Med*. 2016;193(3):227–228.
46. Portegies MLP, Lahousse L, Joos GF, et al. Chronic obstructive pulmonary disease and the risk of stroke: the Rotterdam study. *Am J Respir Crit Care Med*. 2016;193(3):251–258.
47. Soderholm M, Inghammar M, Hedblad B, et al. Incidence of stroke and stroke subtypes in chronic obstructive pulmonary disease. *Eur J Epidemiol*. 2016;31(2):159–168.
48. Morgan AD, Sharma C, Rothnie KJ, et al. Chronic obstructive pulmonary disease and the risk of stroke. *Ann Am Thorac Soc*. 2017;14(5):754–765.
49. Kim YR, Hwang IC, Lee YJ, et al. Stroke risk among patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. *Clinics*. 2018;73:e177.
50. Effing TW, Vercoulen JH, Bourbeau J, et al. Definition of a COPD self-management intervention: international expert group consensus. *Eur Respir J*. 2016;48(1):46–54.
51. Baird C, Lovell J, Johnson M, et al. The impact of cognitive impairment on self-management in chronic obstructive pulmonary disease: a systematic review. *Respir Med*. 2017;129:130–139.
52. Duloher MM, Schroeder DR, Benzo R. Cognitive function and living situation in COPD: is there a relationship with self-management and quality of life? *Int J COPD*. 2015;10:1883–1889.
53. Benzo R, Kirsch JL, Duloher MM, et al. Emotional intelligence: a novel outcome associated with wellbeing and self-management in chronic obstructive pulmonary disease. *Ann Am Thorac Soc*. 2016;13(1):10–16.

54. Meek P, Lareau SC, Anderson D. Memory for symptoms in COPD patients: how accurate are their reports? *Eur Respir J.* **2001**;18(3):474–481.
55. Allen SC, Ragab S. Ability to learn inhaler technique in relation to cognitive scores and tests of praxis in old age. *Postgrad Med J.* **2002**;78:37–39.
56. Brega AG, Grigsby J, Kooker R, et al. The impact of executive cognitive functioning on rates of smoking cessation in the San Luis Valley health and aging study. *Age Ageing.* **2008**;37(5):521–525.
57. Fox AT, Martin LE, Bruce J, et al. Executive function fails to predict smoking outcomes in a clinical trial to motivate smokers to quit. *Drug Alcohol Depend.* **2017**;175:227–231.
58. Cohen-Mansfield J. Predictors of smoking cessation in old-old age. *Nicotine Tob Res.* **2016**;18(7):1675–1679.
59. Ozyemisci-Taskiran O, Bozkurt SO, Kokturk N, et al. Is there any association between cognitive status and functional capacity during exacerbation of chronic obstructive pulmonary disease? *Chron Respir Dis.* **2015**;12(3):247–255.
60. Yazar EE, Aydin S, Gunluoglu G, et al. Clinical effects of cognitive impairment in patients with chronic obstructive pulmonary disease. *Chron Respir Dis.* **2018**;15(3):306–314.
61. Cleutjens FAHM, Spruit MA, Ponds RWHM, et al. The impact of cognitive impairment on efficacy of pulmonary rehabilitation in patients with COPD. *JAMDA.* **2017**;18(5):420–426.
62. Schure MB, Borson S, Nguyen HQ, et al. Associations of cognition with physical functioning and health-related quality of life among COPD patients. *Respir Med.* **2016**;114:46–52.
63. Martinez CH, Richardson CR, Han MK, et al. Chronic obstructive pulmonary disease, cognitive impairment, and development of disability: the Health and Retirement study. *Ann Am Thorac Soc.* **2014**;11(9):1362–1370.
64. Chang SS, Chen S, McAvay GJ, et al. Effect of coexisting chronic obstructive pulmonary disease and cognitive impairment on health outcomes in older adults. *J Am Geriatr Soc.* **2012**;60(10):1839–1846.
65. Dodd JW, Novotny P, Sciurba FC, et al. Executive function, survival, and hospitalization in chronic obstructive pulmonary disease: a longitudinal analysis of the National Emphysema Treatment Trial (NETT). *Ann Am Thorac Soc.* **2015**;12(10):1473–1481.
66. Antonelli Incalzi R, Corsonello A, Pedone C, et al. Drawing impairment predicts mortality in severe COPD. *Chest.* **2006**;130(6):1687–1694.
67. Yohannes AM, Raue PJ, Kanellopoulos D, et al. Predictors of all-cause mortality in patients with severe COPD and major depression admitted to a rehabilitation hospital. *Chest.* **2016**;149(2):467–473.
68. Alexandre F, Heraud N, Varray A. Is nocturnal desaturation a trigger for neuronal damage in chronic obstructive pulmonary disease? *Med Hypotheses.* **2015**;84:25–30.
69. Barnes PJ. Chronic obstructive pulmonary disease: effects beyond the lungs. *PLoS Med.* **2010**;7(3):e1000220.
70. Antonelli Incalzi R, Marra C, Giordano A, et al. Cognitive impairment in chronic obstructive pulmonary disease – a neuropsychological and spect study. *J Neurol.* **2003**;250(3):325–332.
71. Ortapamuk H, Naldoken S. Brain perfusion abnormalities in chronic obstructive pulmonary disease: comparison with cognitive impairment. *Ann Nucl Med.* **2006**;20(2):99–106.
72. Teppema LJ, Dahan A. The ventilatory response to hypoxia in mammals: mechanisms, measurement, and analysis. *Physiol Rev.* **2010**;90(2):675–754.
73. Sicard KM, Duong TQ. Effects of hypoxia, hyperoxia, and hypercapnia on baseline and stimulus-evoked BOLD, CBF, and CMRO₂ in spontaneously breathing animals. *Neuroimage.* **2005**;25(3):850–858.
74. Sumiyoshi A, Suzuki H, Shimokawa H, et al. Neurovascular uncoupling under mild hypoxic hypoxia: an EEG-fMRI study in rats. *J Cereb Blood Flow Metab.* **2012**;32(10):1853–1858.
75. Marshall O, Uh J, Lurie D, et al. The influence of mild carbon dioxide on brain functional homotopy using resting-state fMRI. *Hum Brain Mapp.* **2015**;36(10):3912–3921.
76. Hartmann SE, Pialoux V, Leigh R, et al. Decreased cerebrovascular response to CO₂ in post-menopausal females with COPD: role of oxidative stress. *Eur Respir J.* **2012**;40:1354–1361.
77. Nguyen JC, Killcross AS, Jenkins TA. Obesity and cognitive decline: role of inflammation and vascular changes. *Front Neurosci.* **2014**;8:375.
78. Solas M, Milagro FI, Ramirez MJ, et al. Inflammation and gut-brain axis link obesity to cognitive dysfunction: plausible pharmacological interventions. *Curr Opin Pharmacol.* **2017**;37:87–92.
79. Siervo M, Harrison SL, Jagger C, et al. Metabolic syndrome and longitudinal changes in cognitive function: a systematic review and meta-analysis. *J Alzheimer's Disease.* **2014**;41(1):151–161.
80. Panza F, Frisardi V, Capurso C, et al. Metabolic syndrome and cognitive impairment: current epidemiology and possible underlying mechanisms. *J Alzheimer's Disease.* **2010**;21(3):691–724.
81. Schram MT, Euser SM, De Craen AJ, et al. Systemic markers of inflammation and cognitive decline in old age. *J Am Geriatr Soc.* **2007**;55(5):708–716.
82. Crisan AF, Oancea C, Timar B, et al. Cognitive impairment in chronic obstructive pulmonary disease. *PLoS One.* **2014**;9(7):e102468.
83. Pfistermeister B, Tümen T, Gassmann K-G, et al. Anticholinergic burden and cognitive function in a large German cohort of hospitalized geriatric patients. *PLoS ONE.* **2017**;12(2):e0171353.
84. Jessen F, Kaduszkiewicz H, Daerr M, et al. Anticholinergic drug use and risk for dementia: target for dementia prevention. *Eur Arch Psychiatry Clin Neurosci.* **2010**;260(Suppl 2):S111–S115.
85. Gray SL, Anderson ML, Dublin S, et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. *JAMA Intern Med.* **2015**;175(3):401–407.
86. Fox C, Richardson K, Maidment ID, et al. Anticholinergic medication use and cognitive impairment in the older population: the Medical Research Council cognitive function and ageing study. *J Am Geriatr Soc.* **2011**;59:1477–1483.
87. Heredia JL. Tiotropium bromide: an update. *Open Respir Med J.* **2009**;3:43–52.
88. Joels M. Corticosteroid effects in the brain: U-shape it. *Trends Pharmacol Sci.* **2006**;27(5):244–250.
89. Wolkowitz OM, Lupien SJ, Bigler ED. The “steroid dementia syndrome”: a possible model of human glucocorticoid neurotoxicity. *Neurocase.* **2007**;13(3):189–200.
90. Cipriani G, Picchi L, Vedovello M, et al. Reversible dementia from corticosteroid therapy. *Clin Geriatr.* **2012**;20(7):3841.
91. Walters JA, Tan DJ, White CJ, et al. Different durations of corticosteroid therapy for exacerbations of chronic obstructive pulmonary disease. *Cochrane Database Syst Rev.* **2018**;3:CD006897.
92. Wolkowitz OM, Lupien SJ, Bigler ED. The “steroid dementia syndrome”: a possible model of human glucocorticoid neurotoxicity. *Neurocase.* **2007**;13:189–200.
93. Zhang X, Cai X, Shi X, et al. Chronic obstructive pulmonary disease as a risk factor for cognitive dysfunction: a meta-analysis of current studies. *J Alzheimer's Disease.* **2016**;52:101–111.
94. Tulek B, Atalay NB, Yildirim G, et al. Cognitive function in chronic obstructive pulmonary disease: relationship to global initiative for chronic obstructive lung disease 2011 categories. *Respirology.* **2014**;19(6):873–880.
95. Wedzicha JA, Seemungal TAR. COPD exacerbations: defining their cause and prevention. *Lancet.* **2007**;370(9589):786–796.
96. Cebron Lipovec N, Beijers RJ, Van den Borst B, et al. The prevalence of metabolic syndrome in chronic obstructive pulmonary disease: a systematic review. *COPD.* **2016**;13(3):399–406.
97. Andreou G, Vlachos F, Makanikas K. Effects of chronic obstructive pulmonary disease and obstructive sleep apnea on cognitive functions: evidence for a common nature. *Sleep Disord.* **2014**;2014:768210.
98. Daulatzai MA. Pathogenesis of cognitive dysfunction in patients with obstructive sleep apnea: a hypothesis with emphasis on the nucleus tractus solitarius. *Sleep Disord.* **2012**;2012:251096.
99. Olaithe M, Bucks RS, Hillman DR, et al. Cognitive deficits in obstructive sleep apnea: insights from a meta-review and comparison with deficits observed in COPD, insomnia, and sleep deprivation. *Sleep Med Rev.* **2018**;38:39–49.

100. Aras YG, Tunc A, Gungen BD, et al. The effects of depression, anxiety and sleep disturbances on cognitive impairment in patients with chronic obstructive pulmonary disease. *Cogn Neurodyn*. 2017;11(6):565–571.
101. Fritzsche A, Watz H, Magnussen H, et al. Cognitive biases in patients with chronic obstructive pulmonary disease and depression - a pilot study. *Br J Health Psychol*. 2013;18:827–843.
102. Viscogliosi G, Donfrancesco C, Palmieri L, et al. The metabolic syndrome and 10-year cognitive and functional decline in very old men - a population-based study. *Arch Gerontol Geriatr*. 2017;70:62–66.
103. Alfaro FJ, Lioutas VA, Pimentel DA, et al. Cognitive decline in metabolic syndrome is linked to microstructural white matter abnormalities. *J Neurol*. 2016;263(12):2505–2514.
104. Assuncao N, Sudo FK, Drummond C, et al. Metabolic syndrome and cognitive decline in the elderly: a systematic review. *PLoS One*. 2018;13(3):e0194990.
105. Overman MJ, Pendleton N, O'Neill TW, et al. Glycemia but not the metabolic syndrome is associated with cognitive decline: findings from the European male ageing study. *Am J Geriatr Psychiatry*. 2017;25(6):662–671.
106. Grant I, Heaton RK, McSweeney AJ, et al. Neuropsychologic findings in hypoxemic chronic obstructive pulmonary disease. *Arch Intern Med*. 1982;142(8):1470–1476.
107. Ling J, Heffernan T. The cognitive deficits associated with second-hand smoking. *Front Psychiatry*. 2016;7:46.
108. Swan GE, Lessov-Schlaggar CN. The effects of tobacco smoke and nicotine on cognition and the brain. *Neuropsychological Rev*. 2007;17:259–273.
109. Waisman Campos M, Serebrisky D, Castaldelli-Maia JM. Smoking and cognition. *Curr Drug Abuse Rev*. 2016;9:1–4.
110. Qiao D, Seidler FJ, Slotkin TA. Oxidative mechanisms contributing to the developmental neurotoxicity of nicotine and chlorpyrifos. *Toxicol Appl Pharmacol*. 2005;206(1):17–26.
111. Zhang X, Salmeron BJ, Ross TJ, et al. Anatomical differences and network characteristics underlying smoking cue reactivity. *NeuroImage*. 2011;54(1):131–141.
112. Zhang X, Salmeron BJ, Ross TJ, et al. Factors underlying prefrontal and insula structural alterations in smokers. *NeuroImage*. 2011;54(1):42–48.
113. Yu R, Zhao L, Lu L. Regional grey and white matter changes in heavy male smokers. *PLoS One*. 2011;6(11):e27440.
114. Dal Negro RW, Bonadiman L, Tognella S, et al. Extent and prevalence of cognitive dysfunction in chronic obstructive pulmonary disease, chronic non-obstructive bronchitis, and in asymptomatic smokers, compared to normal reference values. *Int J COPD*. 2014;26(9):675–683.
115. Torres-Sanchez I, Rodriguez-Alzueta E, Cabrera-Martos I, et al. Cognitive impairment in COPD: a systematic review. *Jornal Brasileiro de Pneumologia*. 2015;41(2):182–190.
116. Lai JS, Hiles S, Bisquera A, et al. A systematic review and meta-analysis of dietary patterns and depression in community-dwelling adults. *Am J Clin Nutr*. 2014;99(1):181–197.
117. Abbatecola AM, Russo M, Barbieri M. Dietary patterns and cognition in older persons. *Curr Opin Clin Nutr Metab Care*. 2018;21(1):10–13.
118. Bazinet RP, Layé S. Polyunsaturated fatty acids and their metabolites in brain function and disease. *Nat Rev Neurosci*. 2014;15(12):771–785.
119. Radley J, Morilak D, Viau V, et al. Chronic stress and brain plasticity: mechanisms underlying adaptive and maladaptive changes and implications for stress-related CNS disorders. *Neurosci Biobehav Rev*. 2015;58:79–91.
120. Marin M-F, Lord C, Andrews J, et al. Chronic stress, cognitive functioning and mental health. *Neurobiol Learn Mem*. 2011;96(4):583–595.
121. Sandi C. Stress and cognition. *Wiley Interdiscip Rev Cogn Sci*. 2013;4(3):245–261.
122. Allen AP, Dinan TG, Clarke G, et al. A psychology of the human brain-gut-microbiome axis. *Soc Personal Psychol Compass*. 2017;11(4):e12309.
123. Martin CR, Preedy VR, Abbatecola AM, editors. Diet and nutrition in dementia and cognitive decline. London, England: Academic Press; 2015.
124. Smyth A, Dehghan M, O'Donnell M, et al. Healthy eating and reduced risk of cognitive decline: a cohort from 40 countries. *Neurology*. 2015;84(22):2258–2265.
125. Collins PF, Elia M, Kurukulaarachy RJ, et al. The influence of deprivation on malnutrition risk in outpatients with chronic obstructive pulmonary disease (COPD). *Clin Nutr*. 2018;37(1):144–148.
126. Horadagoda C, Dinihan T, Roberts M, et al. Body composition and micronutrient deficiencies in patients with an acute exacerbation of chronic obstructive pulmonary disease. *Intern Med J*. 2017;47(9):1057–1063.
127. Van de Bool C, Mattijssen-Verdonschot C, Van Melick PP, et al. Quality of dietary intake in relation to body composition in patients with chronic obstructive pulmonary disease eligible for pulmonary rehabilitation. *Eur J Clin Nutr*. 2014;68(2):159–165.
128. Blondell SJ, Hammersley-Mather R, Veerman JL. Does physical activity prevent cognitive decline and dementia? A systematic review and meta-analysis of longitudinal studies. *BMC Public Health*. 2014;14:510.
129. Tudor-Locke C, Craig CL, Aoyagi Y, et al. How many steps/day are enough? For older adults and special populations. *Int J Behav Nutr Phys Activity*. 2011;8:80.
130. Kobayashi Y, Takahashi Y, Seki T, et al. Decreased physical activity associated with executive dysfunction correlates with cognitive impairment among older adults in the community: a retrospective analysis from the Kurihara project. *Dement Geriatr Cogn Dis Extra*. 2016;6(2):350–360.
131. Falck RS, Davis JC, Liu-Ambrose T. What is the association between sedentary behaviour and cognitive function? A systematic review. *Br J Sports Med*. 2017;51(10):800–811.
132. Cinzia G, Roberta P, Fabrizia L, et al. The effects of cognitive training for elderly: results from My Mind project. *Rejuvenation Res*. 2016;19(6):485–494.
133. Shao YK, Mang J, Li PL, et al. Computer-based cognitive programs for improvement of memory, processing speed and executive function during age-related cognitive decline: a meta-analysis. *PLoS One*. 2015;10(6):e0130831.
134. Antonelli Incalzi R, Corsonello A, Trojano L, et al. Cognitive training is ineffective in hypoxemic COPD: a six-month randomized controlled trial. *Rejuvenation Res*. 2008;11(1):239–250.
- The only paper to date investigating the efficacy of cognitive training in patients with COPD.
135. Szuhany KL, Bugatti M, Otto MW. A meta-analytic review of the effects of exercise on brain-derived neurotrophic factor. *J Psychiatr Res*. 2015;60:56–64.
136. Chen HT, Chung YC, Chen YJ, et al. Effects of different types of exercise on body composition, muscle strength, and IGF-1 in the elderly with sarcopenic obesity. *J Am Geriatr Soc*. 2017;65(4):827–832.
137. Pasco JA, Williams LJ, Jacka FN, et al. Sarcopenia and the common mental disorders: a potential regulatory role of skeletal muscle on brain function? *Curr Osteoporos Rep*. 2015;13(5):351–357.
138. Leal G, Afonso PM, Salazar IL, et al. Regulation of hippocampal synaptic plasticity by BDNF. *Brain Res*. 2015;1621:82–101.
139. Aquino G, Iuliano E, Di Cagno A, et al. Effects of combined training vs aerobic training on cognitive functions in COPD: a randomized controlled trial. *Int J COPD*. 2016;11:711–718.
140. Etnier JL, Berry M. Fluid intelligence in an older COPD sample after short- or long-term exercise. *Med Sci Sports Exerc*. 2001;33(10):1620–1628.
141. Mons U, Schottker B, Muller H, et al. History of lifetime smoking, smoking cessation and cognitive function in the elderly population. *Eur J Epidemiol*. 2013;28(10):823–831.
142. Martínez-Lapiscina EH, Clavero P, Toledo E, et al. Mediterranean diet improves cognition: the PREDIMED-NAVARRA randomised trial. *J Neurology, Neurosurg Psychiatry*. 2013;84(12):1318–1325.
143. McEvoy CT, Guyer H, Langa KM, et al. Neuroprotective diets are associated with better cognitive function: the health and retirement study. *J Am Geriatr Soc*. 2017;65(8):1857–1862.

- **Shows that a healthy dietary pattern is associated with lower likelihood of cognitive dysfunctioning.**

144. Tangney CC, Li H, Wang Y, et al. Relation of DASH- and Mediterranean-like dietary patterns to cognitive decline in older persons. *Neurology*. 2014;83(16):1410–1416.
145. Gibson GE, Pulsinelli W, Blass JP, et al. Brain dysfunction in mild to moderate hypoxia. *Am J Med*. 1981;70(6):1247–1254.
146. Spencer SJ, Korosi A, Layé S, et al. Food for thought: how nutrition impacts cognition and emotion. *npj Science of Food*. 2017;1:7.
147. Roebuck-Spencer TM, Glen T, Puente AE, et al. Cognitive screening tests versus comprehensive neuropsychological test batteries: a National Academy of Neuropsychology education paper. *Arch Clin Neuropsychol*. 2017;32(4):491–498.